Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Brain boost in a packet? new study tests hydrate heroes on mental health

NCT ID NCT07241260

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This 12-week study will test whether a daily supplement called Hydrate Heroes can improve brain activity, mood, and thinking skills in 48 healthy adults aged 18 to 65. Participants will take either 3 or 6 packets per day, or no supplement, and will have their brain waves measured and complete surveys about their mental health. The goal is to see if the supplement has any real effect on mental and neurological well-being.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 48 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Aug 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age between 18 and 65 years at time of consent. * Fluent in English (able to read, write, speak, and understand English). * Generally healthy, without chronic medical conditions (see Exclusion 10.3). * Willing and able to attend three in-person study visits over an approximate 12-week period (enrollment, \~6 weeks, \~12 weeks). * Willing to consume assigned Hydrate Heroes packets as directed (6 sticks/day, 3 sticks/day, or no supplement for control). * Willing to log daily water intake and number of Hydrate Heroes packets consumed in the study's online tracking system. * Capable of providing informed consent. Exclusion Criteria: * Neurological or Psychiatric Conditions * History of epilepsy, recurrent seizures, severe head injury, or other significant neurological disorders. * Current diagnosis of major psychiatric disorders (e.g., schizophrenia, bipolar disorder, severe major depressive disorder). · Cardiovascular or Renal Conditions * Chronic kidney disease, congestive heart failure, or any condition requiring medically supervised fluid restriction. * Documented electrolyte imbalance (e.g., hyponatremia, hypokalemia) within the past 6 months. * Medication and Supplement Conflicts * Use of medications known to alter EEG readings (e.g., benzodiazepines, antiepileptics, antipsychotics). * Use of high-dose diuretics or other drugs that substantially affect hydration status. * Concurrent use of any supplements containing one or more key ingredients of Hydrate Heroes - adaptogenic mushroom blends, magnesium, potassium, zinc, vitamin D₃, vitamin C (including Amla), electrolytes, or elderberry - that cannot be safely discontinued for the 12-week study duration. * Reproductive Status * Pregnant or currently breastfeeding. * Compliance Risk * Inability or unwillingness to reliably follow the hydration/supplement protocol or complete daily logging. * Inability to attend scheduled visits or follow instructions.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hydration status are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anxiety disorder Depression Psychological Well-Being

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University of South Florida

    Tampa, Florida, 33620, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.